Article Per Year (5 Year)
p-Index From 2020 - 2025
0.408
P-Index
This Author published in this journals
All Journal Cermin Dunia Kedokteran
Putra, Muhammad Alifian Remifta
Unknown Affiliation
Health Professions

Published : 2 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 2 Documents
Search

 1 
Tata Laksana Terkini Dermatitis Atopik Sedang dan Berat: Dari Patogenesis hingga Terobosan Tata Laksana. Putra, Muhammad Alifian Remifta; Wangsaputra, Vincent Kharisma; Penantian, Raya Makarim
Cermin Dunia Kedokteran Vol 51 No 7 (2024): Kedokteran Umum
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i7.1096

Abstract

Atopic dermatitis (AD), characterized by recurrent eczematous lesions and pruritus, is a major contributor to the total global burden of disability. The common management practice includes patient education and topical emollients and is heavily reliant on the use of anti-inflammatory agents with systemic corticosteroids. Monoclonal antibodies provide a novel, targeted approach towards specific cytokines. This study aims to highlight the novel systemic therapeutic drug aimed at specific targets. A comprehensive literature review utilizes databases including EMBASE, EBSCOhost, PubMed, Scopus, and Wiley Online Library, using keywords: “monoclonal antibody” AND “therapy” AND “atopic dermatitis”. Relevant papers containing different updates in atopic dermatitis management and the utilization of monoclonal antibodies are included in this review. The current regimen of monoclonal antibodies offers better management of moderate-to-severe AD. Monoclonal antibodies have become a promising therapy as they demonstrate better therapeutic effects in terms of skin barrier protection and anti-inflammatory and pruritusreducing effects. However, its application still faces various challenges such as side effects and infections. The heterogeneity and relapsing nature also add to the complexity and risk profile of AD management.
Tata Laksana Komprehensif Terkini Penanganan Re-Emergensi Hand, Foot, and Mouth Disease (HFMD) di Indonesia: Tinjauan Lingkup: Tinjauan Pustaka Putra, Muhammad Alifian Remifta
Cermin Dunia Kedokteran Vol 51 No 10 (2024): Infeksi
Publisher : PT Kalbe Farma Tbk.

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.55175/cdk.v51i10.1122

Abstract

Hand, foot, and mouth disease (HFMD) is an exanthematous disease with the main manifestation of a maculopapular rash eruption on the hands, feet, and mouth accompanied by fever with potentially serious complications in children under five-years-old. Indonesia has a recurring cycle of HFMD outbreaks, making it a re-emergent disease. The author conducted a systematic search in three databases, including Pubmed, Wiley Online Library, and Science Direct, with the keywords "hand, foot, and mouth disease,"enterovirus", and "therapy," published from 2000 until 2023. A total of 791 studies were included in the analysis, and their quality was assessed using the Newcastle-Ottawa Scale. The currently available comprehensive HFMD management includes prevention, therapy, and complication management. Current research has not succeeded in uncovering a definitive treatment; thus, management focused on symptomatics, followed by isolation with good oral and skin care. In severe cases, available options include antiviral therapy and intravenous immunoglobulin, along with respiratory and blood circulation system support. Research has shown that the inactivated Enterovirus A71 (EV-A71) vaccine is the most effective and cost-effective option. However, the evolution of enterovirus epidemiology caused one agent intervention that will be inadequate in the future; thus, developing definitive treatments and effective multivalent vaccines is essential.
Co-Authors Penantian, Raya Makarim Wangsaputra, Vincent Kharisma